6 active not recruiting, 2 completed, 1 recruiting, 1 unknown. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Active not recruiting 6, Completed 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow B Acute Lymphoblastic Leukemia: new trials by email Literature Review of B Acute Lymphoblastic Leukemia trials Research Report on B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2023-04-26 | 2026-10-08 |
| Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1 - B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 26 | 2023-03-15 | 2024-05-29 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL) PBLTT52CAR19 - B Acute Lymphoblastic Leukemia | Phase 1 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 9 | 2020-08-12 | 2024-03-07 |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 33 | 2017-10-20 | 2026-06-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 56 | 2017-09-01 | 2025-11-18 |
| CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) AUTO3 (CD19/22 CAR T cells - B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Autolus Limited | 23 | 2017-06-26 | 2021-02-01 |
| A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia prophylactic 4SCAR19 cells - B Acute Lymphoblastic Leukemia | Phase 1 | Unknown | The First People's Hospital of Yunnan | 30 | 2015-03-01 | 2016-11-18 |
| Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis - B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 71 | 2014-10-16 | 2026-08-05 |
Burkitt Lymphoma (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Neoplasm, Residual (2) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Recurrence (1)
DNA Virus Infections (10) · Epstein-Barr Virus Infections (10) · Hemic and Lymphatic Diseases (10) · Herpesviridae Infections (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Infections (10) · Lymphatic Diseases (10) · Lymphoma (10) · Lymphoma, B-Cell (10) · Lymphoma, Non-Hodgkin (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Tumor Virus Infections (10)
Cyclophosphamide (4) · Biopsy (2) · Immunotherapy, Adoptive (2) · Methotrexate (2) · Prednisone (2) · Specimen Handling (2) · deltacortene (2) · fludarabine phosphate (2) · merphos (2) · prednylidene (2) · venetoclax (2) · CT-P10 (1) · Cytarabine (1) · Dasatinib (1) · Daunorubicin (1)
City of Hope Medical Center (3) · Stanford University (2) · Assistance Publique - Hôpitaux de Paris (1) · Autolus Limited (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · OHSU Knight Cancer Institute (1) · The First People's Hospital of Yunnan (1)
United States (6) · United Kingdom (2) · China (1) · France (1)
Ibrahim Aldoss (2) · Ajay Vora, Prof, MD (1) · Crystal Mackall (1) · Huang Jianzhang, Doctor (1) · Ibrahim T Aldoss (1) · Jessica T Leonard (1) · Kanchan Rao, PhD, MD (1) · Lori Muffly, MD, MS (1) · Paul Veys, PhD, MD (1) · Waseem Qasim, Prof (1)
PMID 42341322, PMID 32772769, PMID 32929049, PMID 34312556, PMID 34515338, PMID 34889384, PMID 36288281, PMID 36821767, PMID 38968138, PMID 41671463
P30CA033572 (2), 2016 (1)